Genomic Landscapes for Neurodegenerative Diseases
Accelerate Your Understanding of the Genomic Drivers of Disease
Genomenon’s AI-Driven Genomic Landscapes for Neurodegenerative Diseases provides profound and actionable insight into the genetic drivers and clinical presentation of Neurodegenerative disease so your team can get to the business of finding treatments faster. The first four diseases included are Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Wilson Disease, and Alzheimer Disease.
Use Cases for Genomic Landscapes
Biomarker identification and validation
Inclusion/exclusion criteria selection for clinical trials
Support for CDx development and regulatory submission
Request Access to the Genomic Landscape
NEW REPORT: Key Findings from the Genomic Landscape for ALS
This comprehensive report reveals research-driven insights from Genomenon’s comprehensive Genomic Landscape for Amyotrophic Lateral Sclerosis (ALS), and their implications for drug development and discovery within Pharma.
-
Expansion of the list of causative genes and variants for ALS
-
Uncovered trends in Age at Onset and Rate of Progression
-
New data on the prevalence of gene mutations in ALS
-
Validation of the novel utility of the Genomic Landscape for ALS
Download the ALS Report →
Benefits of Genomic Landscapes
UNCOVER
3-10X MORE TARGETS
Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards
GAIN INSIGHT
INTO DISEASE MECHANISM
Better understand the role of pathogenic variants and their functional consequence on disease presentation, backed by evidence
IDENTIFY
MORE OF THE RIGHT PATIENTS
Identify all genetic drivers and pinpoint which variants are known to be pathogenic according to ACMG clinical standards
DE-RISK
CLINICAL TRIAL OUTCOMES
De-risk your neurodegenerative disease program by applying the genetic knowledge gained by working with Genomenon
Request A Scientific Briefing
Novel Insights Delivered by Genomic Landscapes
In this LRRK2 example, Genomenon identified all genomic drivers associated with Parkinson disease, finding 10 times the pathogenic variants in less than 20 days as compared to a previous effort taking 20 manual staff-months. Genomenon’s Genomic Landscapes provide essential information specific to the protein domains as well as novel insight into the mechanism of action.
LRRK2 Pathogenic & Likely Pathogenic Variants
Identify hotspot and regions of interest, valuable targets, and focus your efforts.
LRRK2 Variants with Functional Effects
Gain insight into functional consequence and mechanism of action.
Request a Scientific Briefing
Genomic Landscapes for Neurodegenerative Diseases Deliver:
A comprehensive genomic database of clinically relevant genes and disease-causing variants
Every gene and variant curated for clinical relevance and functional significance
Every scientific and clinical assertion supported by empirical evidence
Each Genomic Landscape includes an Executive Summary with notable results and actionable information, including ACMG variant classification, clinical characteristics of the disease, genetic information such as penetrance, inheritance pattern and risk/protective alleles, and functional consequences.
